Summary Neomorph has raised $100 million to advance its molecular glue platform, reinforcing investor confidence in next-generation targeted protein degradation technologies. What Happened The company secured $100M in financing to expand development of its molecular glue therapeutics platform. The announcement…
Summary Pfizer announced the closure of its South San Francisco research site, citing underutilization and broader pressures in the biotech funding environment. The move reflects ongoing post-pandemic restructuring across large pharmaceutical companies and signals shifts in R&D footprint strategy. What…
Summary Gilead Sciences has agreed to acquire German biotech Tubulis in a deal worth up to $5 billion, significantly expanding its antibody-drug conjugate (ADC) platform capabilities. The transaction underscores the strategic importance of ADC technologies in next-generation oncology pipelines. What…
Summary Astellas has declined to exercise its option on AviadoBio’s AAV-based gene therapy program targeting frontotemporal dementia (FTD), but the program will continue through nonprofit funding support. The development highlights an alternative pathway for sustaining high-risk, rare-disease programs despite pharmaceutical…
Summary Fortress Biotech, through its subsidiary Cyprium Therapeutics, has completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million following the FDA approval of ZYCUBO (copper histidinate) for Menkes disease. The transaction represents a significant…
